艾德生物(300685.SZ):2020年度擬申請累計總額不超5億元的綜合授信額度
格隆匯4月13日丨艾德生物(300685.SZ)公佈,公司第二屆董事會第十二次會議召開,審議通過《關於2020年度公司向銀行申請綜合授信額度的議案》。
為了滿足公司生產經營及未來發展需要,2020年度公司擬向銀行申請累計總額不超過5億元人民幣(或等值外幣)的綜合授信額度(最終以各銀行實際核准的信用額度為準),上述綜合授信額度,主要用於短期流動資金貸款、銀行承兑匯票、國內信用證、涉外信用證等業務。以上綜合授信額度不等於公司的實際融資金額,公司具體融資金額將根據自身運營的實際需求確定。上述綜合授信事項的期限為一年,自2019年度股東大會通過之日起至2020年度股東大會召開日止。授權公司董事長簽署相關文件。
該議案尚需提交公司2019年度股東大會審議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.